key: cord-1011614-8otl3781
authors: Shafi, Ahmed M. A.; Shaikh, Safwan A.; Shirke, Manasi M.; Iddawela, Sashini; Harky, Amer
title: Cardiac manifestations in COVID‐19 patients—A systematic review
date: 2020-07-11
journal: J Card Surg
DOI: 10.1111/jocs.14808
sha: b5689fcfc7182aec80cab0bf1f638ba7a7599e62
doc_id: 1011614
cord_uid: 8otl3781

OBJECTIVES: The coronavirus disease‐2019 (COVID‐19) pandemic has resulted in the worst global pandemic of our generation, affecting 215 countries with nearly 5.5 million cases. The association between COVID‐19 and the cardiovascular system has been well described. We sought to systematically review the current published literature on the different cardiac manifestations and the use of cardiac‐specific biomarkers in terms of their prognostic value in determining clinical outcomes and correlation to disease severity. METHODS: A systematic literature review across PubMed, Cochrane database, Embase, Google Scholar, and Ovid was performed according to PRISMA guidelines to identify relevant articles that discussed risk factors for cardiovascular manifestations, cardiac manifestations in COVID‐19 patients, and cardiac‐specific biomarkers with their clinical implications on COVID‐19. RESULTS: Sixty‐one relevant articles were identified which described risk factors for cardiovascular manifestations, cardiac manifestations (including heart failure, cardiogenic shock, arrhythmia, and myocarditis among others) and cardiac‐specific biomarkers (including CK‐MB, CK, myoglobin, troponin, and NT‐proBNP). Cardiovascular risk factors can play a crucial role in identifying patients vulnerable to developing cardiovascular manifestations of COVID‐19 and thus help to save lives. A wide array of cardiac manifestations is associated with the interaction between COVID‐19 and the cardiovascular system. Cardiac‐specific biomarkers provide a useful prognostic tool in helping identify patients with the severe disease early and allowing for escalation of treatment in a timely fashion. CONCLUSION: COVID‐19 is an evolving pandemic with predominate respiratory manifestations, however, due to the interaction with the cardiovascular system; cardiac manifestations/complications feature heavily in this disease, with cardiac biomarkers providing important prognostic information.

A total of 1602 articles were found. Following the removal of duplicates, 798 articles were screened. Of these, 616 articles were excluded after applying the inclusion and exclusion criteria. The remaining 182 articles were analyzed in full, of which 61 articles met our inclusion criteria and were included in our analysis. The complete PRISMA flow chart is reported in Figure 1 . Results are divided into risk factors for cardiovascular manifestations, cardiac manifestations, and cardiac-specific biomarkers.

Several risk factors for cardiovascular manifestation in COVID-19

patients have been described and summarized in Table 2 . One of the most important risk factors is the presence of pre-existing cardiovascular comorbidities. Patients with hypertension or any other cardiovascular comorbidity were more likely to develop a cardiovascular complication due to SARS-CoV-2 infection, with a higher proportion of hypertensive patients developing acute heart injury and heart failure. 9 In a study by Yang et al 10 patients with diabetes, the cerebrovascular, and cardiovascular disease had inferior outcomes with an acute cardiac injury one of the common complications, leading to

death. An analysis of 150 patients with COVID-19 demonstrated that hypertension, diabetes, pre-existing CVD, and cerebrovascular disease were responsible for 43%, 18%, 19%, and 10% of all deaths respectively. Of these deaths, 39% were attributed to heart failure or respiratory failure. 11 Other studies have linked hypertension and diabetes as significant risk factors for developing cardiovascular complications. 13, 14 Guo et al 15 Patients with elevated troponin levels had more frequent malignant arrhythmias and higher levels of other cardiac biomarkers.

An Italian retrospective study showed hypercholesterolemia was another significant comorbidity that can predict worse outcomes involving cardiovascular implications. One hundred

eighty-eight patients present in Intensive Care Units across hospitals in Lombardy had hypercholesterolemia, indicating the importance as a risk factor. 16 The commonest risk factor associated with an adverse cardiovascular complication in COVID-19 patients was hypertension (27%) comorbidity which contributed towards cardiac manifestations. CVD and diabetes was seen in 12.1% and 11.5% of patients, respectively.

Heart failure as a complication of pneumonia is common in hospital patients. However, several studies have identified heart failure as a significant manifestation of COVID-19. 14, 17, 18 One of the first studies linking heart failure and COVID-19 involved 191 patients with Heart failure is postulated to occur in COVID-19 patients due to the severe immune system over-reaction resulting in cytokine storm. The virus downregulates the angiotensin-converting enzyme 2 (ACE2), leading to increased levels of Angiotensin II causing increased inflammation, hypertension, and thrombosis. 21 As further data becomes available, the mechanism of heart failure in COVID-19 patients will become clearer and help provide a standard approach to its treatment. 

Patients affected with COVID-19 are at an increased risk of arrhythmias due to underlying comorbidities, polypharmacy, and disease progression. In a study of 137 patients, 7.3% reported palpitations as one of their symptoms. 27 Several studies have concluded that the prevalence of cardiac arrhythmias is higher in critically ill patients compared to non-critically ill patients. 7, 28, 29 Of note, non-specialized clinicians may use multiple concurrent medications that could potentially (synergistically, in some cases) contribute to an increased arrhythmic risk. Several trials are underway testing combination therapies, for instance, a Brazilian study compared low vs high dose chloroquine, in combination with ceftriaxone and azithromycin with or without oseltamivir. 33 This study amongst others was terminated due to safety concerns as 25% of patients in the high-dose arm showed QT prolongation and two experienced ventricular tachycardia before death. Table 4 summarizes the studies used in analyzing the occurrence of arrhythmias in COVID-19 patients.

Myocardial injury in COVID-19 is a recognized phenomenon. Case series include reports of myocarditis, ACS, and spontaneous coronary artery dissection (SCAD) ( 

Cardiac biomarkers are important in recognizing patients that might be presenting with early signs of myocardial injury secondary to COVID-19, 50 as the presence of myocardial injury was associated with over 50% mortality. 14 We summarized studies looking at cardiac-specific biomarkers (CK, CK-MB, Troponin, Myoglobin, and BNP) in Table 6 .

Studies that reported the frequency of elevated cardiac biomarkers, NT- CK-MB (0-5 ng/mL) Myohaemoglobin (0-110ug/L) Cardiac troponin I (ultra-TnI) (0-0.04 ng/mL) NT-proBNP (0-900 pg/mL) CK-MB raised in 10 patients No. of cases with raised CK-MB showed no significant difference between mild, severe, and critical groups.

MYO raised in 29 patients, Ultra-TnI raised in 27 patients, NT-proBNP raised in 34 patients. No. of cases with raised MYO, ultra Tn-I and NT-proBNP significantly higher in severe and critical cases compared to mild (P < .05) NT-proBNP and MYO significantly increased in severe and critical cases compared to mild (P < .0167), but no difference between severe and critical cases.

The increased ultra-TnI significant between mild and severe cases only (P < .0167).

The increased level of MYO, Ultra-TnI, and NT-proBNP was associated with the severity of COVID-19.

The case fatality rate was 22.81% (13/57) in the group with abnormal parameters compared to 5.09% (11/216) in the normal parameter group.

All four parameters significantly higher in the death group compared to alive group (P < .001)

Zhao et al, 76 China Retrospective, single-center CK raised more in severe compared to mild group (26.7% vs 9.8%, P = .018) Severe group tended to suffer damage to the cardiovascular system (26.7% vs 9.8%, P = .04)

Retrospective study 99 (32 critical, 67 noncritical) Mean age in critical group of 63.8 and 42.5 in noncritical group (P < .001), Overall mean age 63.8

High sensitivity troponin T (TNTHSST) NT-proBNP CKMB raised in critical group compared to noncritical group (P = .053) Myoglobin raised in critical group compared to noncritical group (P = .026) TNTHSST raised in critical group compared to noncritical group (P = .000) NT-proBNP raised in critical group compared to noncritical group (P = .022) Critically ill patients showed significant laboratory evidence of myocardial damage compared to noncritical group, TNTHSST (P < .001), CKMB, myoglobin, and NT-proBNP (P < .05). Critically ill patients had increased myocardial damage and cardiac function indexes. High sensitivity troponin I (hs tnI) NT-proBNP higher in the NT-proBNP >0/88.64 pg/mL (P < .001)

Myoglobin was higher in the group in the NT-proBNP >0/ 88.64 pg/mL (P < .001) CK-MB was higher in the NT-proBNP >0/88.64 pg/mL (P < .001) Hs-TnI was higher in the NT-proBNP >0/88.64 pg/mL (P = .001) Univariate analysis showed a hazard ratio (HR) of NT-proBNP associated to in-hospital death was 1.369 (95% CI, 1.217-1.541; P < .001) for an increase of 100 pg/mL Theories addressing the association between COVID-19 and the The lack of large-scale data on cardiogenic shock and COVID-19

makes it difficult to draw any firm conclusions. However, current data informs us that cardiogenic shock is a cardiovascular manifestation that doctors must look out for in COVID-19 patients. Finally, further studies are required to characterize the nature and classification of arrhythmias amidst the COVID-19 pandemic. 61 Ruan et al 11 showed patients that died from COVID-19 the cause of death was respiratory failure and cardiac injury in 33%, supported by Shi et al. 13 The presence of myocardial injury was associated with a significantly worse prognosis. A meta-analysis by Li et al cardiac biomarkers were significantly higher in severe cases compared to milder cases (P < .001), this included troponin (P < .001), CK-MB (P < .001) and NT-proBNP (P = .009) but myoglobin was not (P = .052).

Additionally, death was also higher in patients with acute cardiac injury (P < .001). 62 

Both TnT and NT-proBNP levels increased significantly during the course of hospitalization in those who ultimately died, but no such dynamic changes of TnT or NT-proBNP levels were evident in survivors.

Fan et al 85 | 2005 more rapid escalation of treatment. With a second wave expected by many experts to be worse than the initial wave, clinicians must be aware of the risk factors, the manifestations, and the investigations that could help in preventing such predictions becoming reality.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19 and Multiorgan Response

The impact of COVID-19 on the provision of cardiac surgical services

Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects

Acute myocardial infarction after laboratory-confirmed influenza infection

Risk of myocardial infarction and stroke after acute infection or vaccination

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan

Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

Cardiovascular disease drug therapy, and mortality in Covid-19

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States

Correction to: clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Hospitalization and critical care of 109 decedents with COVID-19 pneumonia in Wuhan, China

Cardiological society of India position statement on COVID-19 and heart failure

The variety of cardiovascular presentations of COVID-19

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

COVID-19 and cardiogenic shock. Different cardiovascular presentations with high mortality

First successful treatment of COVID-19 induced refractory cardiogenic plus vasoplegic shock by combination of pVAD and ECMO-a case report

COVID-19 complicated by acute myocardial infarction with extensive thrombus burden and cardiogenic shock. Cathete Cardiovas Intervn

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan

Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study

Atrial arrhythmias in a patient presenting with coronavirus disease-2019 (COVID-19) infection

Severe sepsis and cardiac arrhythmias

Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. medRxiv

Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study

Current concepts in the diagnosis and management of cytokine release syndrome

Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease

An immunosuppressed Syrian golden hamster model for SARS-CoV infection

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Recognition and initial management of fulminant myocarditis: a scientific statement from the

Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis

Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China

First case of COVID-19 complicated with fulminant myocarditis: a case report and insights

COVID-19-related myocarditis in a 21-year-old female patient

A recovered case of COVID-19 myocarditis and ARDS treated with corticosteroids, tocilizumab

Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19

Multivessel coronary thrombosis in a patient with COVID-19 pneumonia

ST-segment elevation in patients with Covid-19-a case series

Transient ST segment elevation in two patients with COVID-19 and a normal transthoracic echocardiogram

Spontaneous coronary artery dissection in a patient with COVID-19

Spontaneous coronary artery dissection of the left anterior descending artery in a patient with COVID-19 infection

The role of biomarkers in diagnosis of COVID-19-a systematic review

Coronaviruses and the cardiovascular system: acute and long-term implications

Clinical features and treatment of COVID-19 patients in northeast Chongqing

COVID-19 and the cardiovascular system

Cardiovascular disease and the impact of COVID-19

Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded "cardiovascular continuum

Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research

Cardiovascular disease and COVID-19. Diab Metab Syndrome

At the heart of COVID-19

The need to manage the risk of thromboembolism in COVID-19 patients

Seasonal influenza infections and cardiovascular disease mortality

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)

The impact of 2019 novel coronavirus on heart injury: a systematic review and meta-analysis

Clinical characteristics of coronavirus disease 2019 in China

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease

Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

COVID-19 complicated by acute pulmonary embolism and right-sided heart failure. JACC Case Rep

Cardiovascular diseases and COVID-19 mortality and intensive care unit admission: a systematic review and meta-analysis. medRxiv

Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

Fatal eosinophilic myocarditis in a healthy 17-year-old male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2c)

Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Diffuse myocardial inflammation in COVID-19 associated myocarditis detected by multiparametric cardiac magnetic resonance imaging

Pediatric life-threatening coronavirus disease 2019 with myocarditis. Pediatric Infect Dis J

Multivessel spontaneous coronary artery dissection presenting in a patient with severe acute SARS-CoV-2 respiratory infection

Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu

Prognostic value of NT-proBNP in patients with severe COVID-19

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

Analysis of 92 deceased patients with COVID-19

Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Retrospective analysis of clinical features in 101 death cases with COVID-19. medRxiv

Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19)

Cardiac manifestations in COVID-19 patients-A systematic review

The authors declare that there are no conflict of interests.

Ahmed M. A. Shafi https://orcid.org/0000-0002-8910-3713Amer Harky http://orcid.org/0000-0001-5507-5841